London
· Delayed Price · Currency is GBP · Price in USD Xeris Biopharma Holdings Statistics
Total Valuation
Xeris Biopharma Holdings has a market cap or net worth of GBP 426.98 million. The enterprise value is 589.14 million.
| Market Cap | 426.98M |
| Enterprise Value | 589.14M |
Important Dates
The next estimated earnings date is Thursday, March 6, 2025.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +5.01% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 142.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.51 |
| EV / Sales | 3.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -24.47 |
Financial Position
The company has a current ratio of 1.79
| Current Ratio | 1.79 |
| Quick Ratio | 1.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -8.40 |
| Interest Coverage | -1.52 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -8.70% |
| Return on Invested Capital (ROIC) | -11.90% |
| Return on Capital Employed (ROCE) | -19.63% |
| Revenue Per Employee | 370,796 |
| Profits Per Employee | -124,903 |
| Employee Count | 377 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 0.84 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.81% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +38.81% |
| 50-Day Moving Average | 3.39 |
| 200-Day Moving Average | 2.70 |
| Relative Strength Index (RSI) | 53.02 |
| Average Volume (20 Days) | 3,099 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.09 |
Income Statement
In the last 12 months, Xeris Biopharma Holdings had revenue of GBP 139.79 million and -47.09 million in losses. Loss per share was -0.33.
| Revenue | 139.79M |
| Gross Profit | 113.73M |
| Operating Income | -33.70M |
| Pretax Income | -48.96M |
| Net Income | -47.09M |
| EBITDA | -24.67M |
| EBIT | -33.70M |
| Loss Per Share | -0.33 |
Balance Sheet
The company has 51.78 million in cash and 202.17 million in debt, giving a net cash position of -150.39 million.
| Cash & Cash Equivalents | 51.78M |
| Total Debt | 202.17M |
| Net Cash | -150.39M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -21.13M |
| Book Value Per Share | -0.14 |
| Working Capital | 53.56M |
Cash Flow
In the last 12 months, operating cash flow was -23.49 million and capital expenditures -581,958, giving a free cash flow of -24.07 million.
| Operating Cash Flow | -23.49M |
| Capital Expenditures | -581,958 |
| Free Cash Flow | -24.07M |
| FCF Per Share | n/a |
Margins
Gross margin is 81.36%, with operating and profit margins of -24.11% and -33.69%.
| Gross Margin | 81.36% |
| Operating Margin | -24.11% |
| Pretax Margin | -35.02% |
| Profit Margin | -33.69% |
| EBITDA Margin | -17.65% |
| EBIT Margin | -24.11% |
| FCF Margin | n/a |
Dividends & Yields
Xeris Biopharma Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.01% |
| Shareholder Yield | -5.01% |
| Earnings Yield | -11.03% |
| FCF Yield | -5.64% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Xeris Biopharma Holdings has an Altman Z-Score of -1.97. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.97 |
| Piotroski F-Score | n/a |